48 results were returned
By decisions dated 30 July 2018, then confirmed in the appeal by decisions dated 30 August 2018, the Court of Milan dismissed PI requested by ICOS and its licensee Eli Lilly against Sandoz, ascertaining the prima facie ...
The Dutch competition authority, ACM, initiated a market study in 2018 into the effect of the introduction of biosimilars on the competition between TNF alfa inhibitors. TNF-alfa inhibitors are biological medicines that ...
On September 26, 2019, the Higher Regional Court of Düsseldorf confirmed on appeal that Teva Pharmaceutical Industries Ltd. (“Teva”) – one of Bird & Bird’s key clients – is entitled to a preliminary injunction against ...
If a patentee undertakes actions with respect to a patent of the same patent family (e.g. waiving the parent patent of a divisional patent), this is often negatively characterised as playing the “Divisional Game”. We ...
The French so-called “anti-gift” provisions strictly frame the conditions under which companies in the health sector are allowed to provide advantages, in cash or in kind, to healthcare professionals ("HCPs”)
On 26 August 2019, China's National People's Congress passed the final amendments to the Drug Administration Law ("DAL"), which will take effect on 1 December 2019. The DAL was first enacted in 1984, then substantively ...
The Bill of the Law on the organization and transformation of the French healthcare system at the French parliament, adoption of the final version is expected for the end of July.
Biotech and medtech companies operate in an international environment where the composition of their governance bodies is a key criterion of credibility.
On 17 April 2019, the European Parliament approved, by a large majority, an amendment of the Regulation on Supplementary Protection Certificates ("SPCs").
The French Health Data Hub was born officially with the publication on 30 November 2019 of a ministerial decision (arrêté).